Comparative Pharmacology
Head-to-head clinical analysis: FYCOMPA versus LAMICTAL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYCOMPA versus LAMICTAL XR.
FYCOMPA vs LAMICTAL XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
Lamotrigine extended-release tablets: Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 200 mg once daily; maintenance 200–400 mg once daily as adjunctive therapy for epilepsy. For bipolar disorder, dose titration as per prescribing information; typical maintenance 200 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Terminal elimination half-life is approximately 25-33 hours in healthy adults, increasing to 50-60 hours in patients taking valproate, and decreasing to 15-27 hours in patients taking enzyme-inducing drugs like carbamazepine, phenytoin, or phenobarbital.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Primarily renal; ~70% of lamotrigine is excreted in urine as glucuronide conjugates, 10% as parent drug, and 20% via feces.
Category C
Category C
Anticonvulsant
Anticonvulsant